| DATE | TITLE |
| 2009 |
| July 17 |
Policy to Acquire Medications for Treatment of Tuberculosis
- Dear Pharmacist Letter. Communiqué from the Public Health Division, MOHLTC
|
| July 15 |
Notice from the Executive Officer : Reporting Framework for Professional Allowances
|
| May 6 |
Notice from the Executive Officer : Change of Funding Status
Rosiglitazone (Avandia®) and Pioglitazone (Actos® and Generics)
- Q&As for TZD Funding Status Change
|
| May 6 |
Notice from the Executive Officer : Expanded Limited Use Criteria for Clopidogrel (Plavix)
- Q&As for Clopidogrel Expanded LU Criteria
|
| March 3 |
Notice from the Executive Officer - MedsCheck Adjustment Payment to Pharmacies Ending on April 1, 2009
|
| February 23 |
Notice from the Executive Officer : Ongoing Transparency Initiative: Public Posting of Drug Submission Status - Updates
|
| February 4 |
Notice from the Executive Officer : Reminder – Professional Allowance Reporting: July 1, 2008 to December 31, 2008
|
| January 13 |
Notice from the Executive Officer : Academic Detailing Program
- Q&As for Academic Detailing Program
|
| January 9 |
Notice from the Executive Officer : FINAL REMINDER –
6 DAYS LEFT until January 15, 2009 to renew Health Network System (HNS) Agreement |
| January 5 |
Notice from the Executive Officer: 10 DAYS LEFT until January 15, 2009 - Renewal of the Health Network System (HNS) Agreement |
| 2008 |
| December 29 |
Notice from the Executive Officer: 2 WEEKS REMAIN — Renewal of the Health Network System (HNS) Agreement |
| December 22 |
Notice from the Executive Officer: 3 WEEKS REMAIN — Renewal of the Health Network System (HNS) Agreement |
| December 19 |
Notice from the Executive Officer: Health Network System (HNS) Enhancements to Support the Conditions for Payment of Dispensing Fees under the Ontario Drug Benefit (ODB) Program |
| December 17 |
Notice from the Executive Officer: Renewal of the Health Network System (HNS) Subscription Agreement |
| December 1 |
Notice from the Executive Officer : Enhancements to Health Network System to Support the Conditions for Payment of Dispensing Fees under the Ontario Drug Benefit (ODB) Program |
| December 1 |
Notice from the Executive Officer : Announcement of Changes to the Formulary respecting Enalapril Maleate |
| November 17 |
Notice from the Executive Officer : Telephone Request Service for Exceptional Access Program
- Q&As for External Stakeholders
|
| October 29 |
Executive Officer Notice : Completing the New Health Network System (HNS) Agreement
|
| October 27 |
Executive Officer Notice : Price Increase Requests
|
| October 20 |
Notice of Termination and Replacement of Agreement : Ontario Public Drug Programs Subscription Agreement
- Health Network System (HNS) Subscription Agreement for Pharmacy Operators
|
| October 3 |
Notice from the Executive Officer: Public Consultation to Review the definition of Professional Allowance and the Codes of Conduct
|
| October 2 |
Notice from the Executive Officer: Notice of Termination and Replacement of Agreement : Ontario Public Drug Programs Subscription Agreement
|
| September 30 |
Notice From Executive Officer: Implementation Plan To Review The Definition Of Professional Allowance And The Code Of Conduct
|
| September 19 |
Notice from the Executive Officer: Notice Of Cancellation Of Call For Application For Ranitidine Hydrochloride
|
| August 26 |
Notice from the Executive Officer: Drug Submissions Requirement - Revised Letter of Consent
|
| August 22 |
Notice from the Executive Officer Reminder - Professional Allowance Reporting
|
| August 5 |
Notice from the Executive Officer: Claims for ZANTAC® under the Ontario Drug Benefit Program
|
| July 31 |
Notice from the Executive Officer: No Change to the Drug Benefit Price for ZANTAC®
|
| July 28 |
Conditions for Payment of Dispensing Fees under the Ontario Drug Benefit (ODB) Program
- Questions and Answers
|
| July 25 |
Notice from the Executive Officer Re: MedsCheck Guidebook 2nd Ed available on ministry website
|
| July 18 |
Notice from the Executive Officer : Reporting Framework for Professional Allowances
|
| July 16 |
Notice from the Executive Officer: Competitive Agreements Q&As
|
| July 8 |
Notice from the Executive Officer : Ontario Public Drug Programs Competitive Agreement
- Briefing for Stakeholders
|
| June 4 |
Notice from the Executive Officer : Manufacturer Review of Transparency Bulletin |
| May 29 |
Notice from the Executive Officer : Pricing of Products Reimbursed Under the
Exceptional Access Program (EAP) |
| May 16 |
Notice from Executive Officer |
| May 16 |
Notice from Executive Officer: Limited Use (LU) Process Changes
|
| May 13 |
Notice from Executive Officer: Ongoing Transparency Initiative - Public Posting of Drug Submission Status.
|
| April 17 |
Notice from the Executive Officer: Lucentis Questions and Answers |
| April 15 |
Recruitment for Pharmacy Council Members, letter from the Executive Officer |
| March 6
| Notice from the Executive Officer : Reporting Framework for Professional Allowances |
| January 30
| 2008 BBS Notice from the Executive Officer: MedsCheck, Adjustment Payment to Pharmacies - a Reminder |
| 2007 |
| November 15
| Notice from the Executive Officer, BBS Introducing the "Follow-up" MedsCheck, effective November 30, 2007 |
| November 15
| Recruitment for Pharmacy Council Members, letter from the Executive Officer |
| November 13
| Notice from the Executive Officer : Reporting Framework for Professional Allowances |
| October 19
| Notice from the Executive Officer: Reporting Framework for Professional Allowances |
October 1
| Notice to Manufacturers Submission Requirements for
Generic Drug Products |
October 4
| (BBS Nº.7079)
Notice from the Executive Officer: Lead Time Between the Formulary Update and Effective Date |
| September 14
| (BBS Nº.7071)
Notice from the Executive Officer : Reporting Framework for Professional Allowances |
| August 3
| (BBS Nº.7059)
Notice to Pharmacists: Guidelines for the Reimbursement of Extemporaneous Compounds |
| July
| Letter to Pharmacists from the Executive Officer: MedsCheck Update |
| July 13
| Notice to Pharmacists: MedsCheck Update |
| June 4
| (BBS Nº.7035)
Addendum to Notice to Pharmacists dated May 31, 2007 |
| May 31
| (BBS Nº.7032)
Notice to Pharmacists: Use of the MI Code |
| May 29
| (BBS Nº.7029)
MedsCheck Update |
| May 8
| (BBS Nº.7025)
Notice to Pharmacists from Executive Officer: Follow up to April 5, 2007 Notice |
| April 5
| (BBS Nº.7020)
Notice to Pharmacists from the Executive Officer: Process for payment of lost mark-up |
| April 1
| Letter to Pharmacists from the Executive Officer: MedsCheck |
| February 21
| (BBS Nº.7009)
Notice from the Executive Officer: Reporting Framework for Professional Allowances |
| January 15
| (BBS Nº.7004)
Bulletin : Long-Term Care Stock Replenishment Initiative |
| January 3
| (BBS Nº.7002)
Notice from the Executive Officer: Selling and Invoice Pricing of Products |
| 2006 |
| December 18
| (BBS Nº.6086)
Notice from the Executive Officer : Amending Regulations under ODBA and DIDFA |
| November 1
| (BBS Nº.6078)
Notice from the Executive Officer: Resolutions to Implementation Issues |
| October 31
| (BBS Nº.6077)
Message from the Executive Officer : Implementation Issues |
| September 28
| Notice to Pharmacists : Regulation Changes made to the Ontario Drug Benefit Act (ODBA) and the Drug Interchangeability and Dispensing Fee Act (DIDFA) |
| April 13
| (BBS Nº.6029)
Notice to Pharmacists : Bill 102, Transparent Drug System for Patients Act |
